IMMUNE-ONC THERAPEUTICS, INC.

Palo Alto, CA · Founded 2015 · CIK 0001685307 · Biotech · Private

IO-202, a monoclonal antibody that inhibits LILRB4 signaling to treat monocytic acute myeloid leukemia and chronic myelomonocytic leukemia

immune-onc.com →
Grants
$3.2M
2 awards
Sector median: 1
Raised
$7.0M
1 Form D · Sep 2016
120 months since last filing
Contracts
—
No federal contracts on record
Patents
22
3 granted · 19 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$7,003,890
Federal grantDepartment of Health and Human Services · Phase II · Non-clinical Combination Pharmacology Studies and Phase 1 Clinical Development of IO-202 in Acute Myeloid Leukemia (AML)$2,140,000
Federal grantDepartment of Health and Human Services · Phase II · Non-clinical Combination Pharmacology Studies and Phase 1 Clinical Development of IO-202 in Acute Myeloid Leukemia (AML)$1,070,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2369Merida Biosciences——
23703D HEALTH SOLUTIONS, INC.——
2371Helicore, LLC—$2.0M
2372IMMUNE-ONC THERAPEUTICS, INC.—$7.0M
2373Eluciderm Inc.—$3.8M
2374BIO-PATH HOLDINGS, INC.—$18M
2375Indapta Therapeutic——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Xiaoling Charlene LiaoDirector · Executive Officer
  • Liqun LuoDirector
  • Guo-Liang YuDirector

Patents

USPTO · 3 granted of 22
  • Novel ANTI-LILRB4 Antibodies And Derivative Productsapplication
  • Novel LILRB2 Antibodies And Uses Thereofgranted
  • Novel ANTI-LILRB4 Antibodies And Derivative Productsgranted
  • Novel LILRB4 Antibodies And Uses Thereofapplication
  • Combination Therapy Of Lilrb Antagonist And PD-1/PD-L1 Axis Inhibitorapplication
  • Novel LILRB4 Antibodies And Uses Thereofgranted
  • Novel ANTI-LILRB2 Antibodies And Derivative Productsapplication
  • Novel LILRB2 Antibodies And Uses Thereofapplication
  • Novel ANTI-LILRB2 Antibodies And Derivative Productsapplication
  • Novel ANTI-LILRB2 Antibodies And Derivative Productsapplication
  • Novel ANTI-LILRB4 Antibodies And Derivative Productsapplication
  • Novel LILRB2 Antibodies And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.